Arsenic trioxide-based therapy of relapsed acute promyelocytic leukemia: registry results from the european leukemianet

ABSTRACT In 2008, a European registry of relapsed acute promyelocytic leukemia was established by the European LeukemiaNet. Outcome data were available for 155 patients treated with arsenic

trioxide in first relapse. In hematological relapse (_n_=104), 91% of the patients entered complete hematological remission (CR), 7% had induction death and 2% resistance, 27% developed

differentiation syndrome and 39% leukocytosis, whereas no death or side effects occurred in patients treated in molecular relapse (_n_=40). The rate of molecular (m)CR was 74% in

hematological and 62% in molecular relapse (_P_=0.3). All patients with extramedullary relapse (_n_=11) entered clinical and mCR. After 3.2 years median follow-up, the 3-year overall

survival (OS) and cumulative incidence of second relapse were 68% and 41% in hematological relapse, 66% and 48% in molecular relapse and 90 and 11% in extramedullary relapse, respectively.

After allogeneic or autologous transplantation in second CR (_n_=93), the 3-year OS was 80% compared with 59% without transplantation (_n_=55) (_P_=0.03). Multivariable analysis demonstrated

the favorable prognostic impact of first remission duration ⩾1.5 years, achievement of mCR and allogeneic or autologous transplantation on OS of patients alive after induction (_P_=0.03,

_P_=0.01, _P_=0.01) and on leukemia-free survival (_P_=0.006, _P_<0.0001, _P_=0.003), respectively. Access through your institution Buy or subscribe This is a preview of subscription

content, access via your institution ACCESS OPTIONS Access through your institution Subscribe to this journal Receive 12 print issues and online access $259.00 per year only $21.58 per issue

Learn more Buy this article * Purchase on SpringerLink * Instant access to full article PDF Buy now Prices may be subject to local taxes which are calculated during checkout ADDITIONAL

ACCESS OPTIONS: * Log in * Learn about institutional subscriptions * Read our FAQs * Contact customer support SIMILAR CONTENT BEING VIEWED BY OTHERS AN EFFECTIVE AND CHEMOTHERAPY-FREE

STRATEGY OF ALL-TRANS RETINOIC ACID AND ARSENIC TRIOXIDE FOR ACUTE PROMYELOCYTIC LEUKEMIA IN ALL RISK GROUPS (APL15 TRIAL) Article Open access 21 November 2022 ACUTE PROMYELOCYTIC LEUKEMIA

CURRENT TREATMENT ALGORITHMS Article Open access 30 June 2021 LONG-TERM OUTCOME OF CHILDREN WITH ACUTE PROMYELOCYTIC LEUKEMIA: A RANDOMIZED STUDY OF ORAL VERSUS INTRAVENOUS ARSENIC BY

SCCLG-APL GROUP Article Open access 05 December 2023 REFERENCES * Wang ZY, Chen Z . Acute promyelocytic leukemia: from highly fatal to highly curable. _Blood_ 2008; 111: 2505–2015. Article 

CAS  PubMed  Google Scholar  * Degos L, Dombret H, Chomienne C, Daniel MT, Micléa JM, Chastang C _et al_. All-trans-retinoic acid as a differentiating agent in the treatment of acute

promyelocytic leukemia. _Blood_ 1995; 85: 2643–2653. CAS  PubMed  Google Scholar  * Castagnola C, Lunghi M, Corso A, Tajana M, Zappasodi P, Dabusti M _et al_. Management of acute

promyelocytic leukemia relapse in the ATRA era. _Haematologica_ 1998; 83: 714–717. CAS  PubMed  Google Scholar  * Thomas X, Dombret H, Cordonnier C, Pigneux A, Gardin C, Guerci A _et al_.

Treatment of relapsing acute promyelocytic leukemia by all-trans retinoic acid therapy followed by timed sequential chemotherapy and stem cell transplantation. _Leukemia_ 2000; 14:

1006–1013. Article  CAS  PubMed  Google Scholar  * Sanz MA, Labopin M, Gorin NC, de la Rubia J, Arcese W, Meloni G _et al_. Hemotopoietic stem cell transplantation for adults with acute

promyelocytic leukemia in the ATRA era: a survey of the European Cooperative Group for Blood and Marrow Transplantation. _Bone Marrow Transplant_ 2007; 39: 461–469. Article  CAS  PubMed 

Google Scholar  * Lengfelder E, Hofmann WK, Nowak D . Impact of arsenic trioxide in the treatment of acute promyelocytic leukemia. _Leukemia_ 2012; 26: 433–442. Article  CAS  PubMed  Google

Scholar  * Soignet SL, Frankel SR, Douer D, Tallman MS, Kantarjian H, Calleja E _et al_. United States multicenter study of arsenic trioxide in relapsed acute promyelocytic leukemia. _J Clin

Oncol_ 2001; 19: 3852–3860. Article  CAS  PubMed  Google Scholar  * Thomas X, Pigneux A, Raffoux E, Huguet F, Caillot D, Fenaux P . Superiority of an arsenic trioxide-based regimen over a

historic control combining all-trans retinoic acid plus intensive chemotherapy in the treatment of relapsed acute promyelocytic leukemia. _Haematologica_ 2006; 91: 996–997. CAS  PubMed 

Google Scholar  * Sanz MA, Grimwade D, Tallman MS, Lowenberg B, Fenaux P, Estey EH _et al_. Management of acute promyelocytic leukemia: recommendations from an expert panel on behalf of the

European LeukemiaNet. _Blood_ 2009; 113: 1875–1891. Article  CAS  PubMed  Google Scholar  * Meloni G, Diviero D, Vignetti M, Avvisati G, Capria S, Petti MC _et al_. Autologous bone marrow

transplantation for acute promyelocytic leukemia in second remission: prognostic relevance of pretransplant minimal residual disease assessment by reverse transcription polymerase chain

reaction of the PML/RARα fusion gene. _Blood_ 1997; 90: 1321–1325. CAS  PubMed  Google Scholar  * Ramadan SM, Di Veroli A, Camboni A, Breccia M, Iori AP, Aversa F _et al_. Allogeneic stem

cell transplantation for advanced acute promyelocytic leukemia in the ATRA and ATO era. _Haematologica_ 2012; 97: 1731–1735. Article  PubMed  PubMed Central  Google Scholar  * Au WY, Lie AK,

Chim CS, Liang R, Ma SK, Chan CH _et al_. Arsenic trioxide in comparison with chemotherapy and bone marrow transplantation for the treatment of relapsed acute promyelocytic leukaemia. _Ann

Oncol_ 2003; 14: 752–757. Article  CAS  PubMed  Google Scholar  * Lou Y, Qian W, Meng H, Mai W, Tong H, Tong Y _et al_. High efficacy of arsenic trioxide plus all-trans retinoic acid based

induction and maintenance therapy in newly diagnosed acute promyelocytic leukemia. _Leuk Res_ 2013; 37: 37–42. Article  CAS  PubMed  Google Scholar  * Grimwade D, Jovanovic JV, Hills RK,

Nugent EA, Patel Y, Flora R _et al_. Prospective minimal residual disease monitoring to predict relapse of acute promyelocytic leukemia and to direct pre-emptive arsenic trioxide therapy. _J

Clin Oncol_ 2009; 27: 3650–3658. Article  CAS  PubMed  Google Scholar  * Lo Coco F, De Santis S, Esposito A, Divona M, Diverio D . Molecular monitoring of hematologic malignancies: current

and future issues. _Semin Hematol_ 2002; 39: 14–17. Article  CAS  PubMed  Google Scholar  * Esteve J, Escoda L, Martín G, Rubio V, Díaz-Mediavilla J, González M _et al_. Outcome of patients

with acute promyelocytic leukemia failing to front-line treatment with all-trans retinoic acid and anthracycline-based chemotherapy (PETHEMA protocols LPA96 and LPA99): benefit of an early

intervention. _Leukemia_ 2007; 21: 446–452. Article  CAS  PubMed  Google Scholar  * Sanz MA, Fenaux P, Lo Coco F, European APL Group of Experts. Arsenic trioxide in the treatment of acute

promyelocytic leukemia. A review of current evidence. _Haematologica_ 2005; 90: 1231–1235. CAS  PubMed  Google Scholar  * Cheson BD, Bennett JM, Kopecky KJ, Büchner T, Willman CL, Estey EH

_et al_. Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in

Acute Myeloid Leukemia. _J Clin Oncol_ 2003; 21: 4642–4649. Article  PubMed  Google Scholar  * van Dongen JJ, Macintyre EA, Gabert JA, Delabesse E, Rossi V, Saglio G _et al_. Standardized

RT-PCR analysis of fusion gene transcripts from chromosome aberrations in acute leukemia for detection of minimal residual disease. Report of the BIOMED-1 Concerted Action: investigation of

minimal residual disease in acute leukemia. _Leukemia_ 1999; 13: 1901–1928. Article  CAS  PubMed  Google Scholar  * Gabert J, Beillard E, van der Velden VH, Bi W, Grimwade D, Pallisgaard N

_et al_. Standardization and quality control studies of 'real-time' quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease

detection in leukemia - a Europe Against Cancer program. _Leukemia_ 2003; 17: 2318–2357. Article  CAS  PubMed  Google Scholar  * Kaplan EL, Meier P . Non-parametric estimation from

incomplete observation. _J Am Stat Assoc_ 1958; 53: 457–481. Article  Google Scholar  * Cooley TA, Leisenring W, Crowley J, Storer BE . Estimation of failure. Probabilities in the presence

of competing risks: new representation of old estimators. _Stat Med_ 1999; 18: 695–706. Article  Google Scholar  * Gray R . A class of K-sample tests for comparing the cumulative incidence

of a competing risk. _Ann Stat_ 1988; 16: 1141–1151. Article  Google Scholar  * Cox D . Regression models and life tables. _J R Stat Soc B_ 1972; 34: 187–220. Google Scholar  * Pacilli L, Lo

Coco F, Ramadan SM, Gianni L, Pingi A, Remotti D _et al_. Promyelocytic lymphoma of the spine: a case report and review of the literature. _Adv Hematol_ 2010; 2010: 137608. Article  PubMed

  PubMed Central  Google Scholar  * Lou Y, Suo S, Tong Y, Tong H, Qian W, Meng H _et al_. Outcomes and prognostic factors of first relapsed acute promyelocytic leukemia patients undergoing

salvage therapy with intravenous arsenic trioxide and chemotherapy. _Ann Hematol_ 2014; 93: 941–948. Article  CAS  PubMed  Google Scholar  * Au WY, Tam S, Fong BM, Kwong YL . Elemental

arsenic entered the cerebrospinal fluid during oral arsenic trioxide treatment of meningeal relapse of acute promyelocytic leukemia. _Blood_ 2006; 107: 3012–3013. Article  CAS  PubMed 

Google Scholar  * De Botton S, Sanz MA, Chevret S, Dombret H, Martin G, Thomas X _et al_. Extramedullary relapse in acute promyelocytic leukemia treated with all-trans retinoic acid and

chemotherapy. _Leukemia_ 2006; 20: 5–41. Article  Google Scholar  * Montesinos P, Díaz-Mediavilla J, Debén G, Prates V, Tormo M, Rubio V _et al_. Central nervous system involvement at first

relapse in patients with acute promyeolcytic leukemia treated with all-trans retinoic acid and anthracycline monochemotherapy without intrathecal prophylaxis. _Haematologica_ 2009; 94:

1242–1249. Article  CAS  PubMed  PubMed Central  Google Scholar  * Wang H, Cao F, Li J, Li L, Li Y, Shi C _et al_. Arsenic trioxide and mannitol for the treatment of acute promyelocytioc

leukemia relapse in central nervous system. _Blood_ 2014; 124: 1998–2000. Article  CAS  PubMed  PubMed Central  Google Scholar  * Douer D, Hu W, Giralt S, Lill M, DiPersio J . Arsenic

trioxide (trisenox) therapy for acute promyelocytic leukemia in the setting of hematopoietic stem cell transplantation. _Oncologist_ 2003; 8: 132–140. Article  CAS  PubMed  Google Scholar  *

De Botton S, Fawaz A, Chevret S, Dombret H, Thomas X, Sanz M _et al_. Autologous and allogeneic stem-cell transplantation as salvage treatment of acute promyelocytic leukemia initially

treated with all-trans-retinoic acid: a retrospective analysis of the European acute promyelocytic leukemia group. _J Clin Oncol_ 2005; 23: 120–126. Article  CAS  PubMed  Google Scholar  *

Thirugnanam R, George B, Chendamarai E, Lakshmi KM, Balasubramanian P, Viswabandya A _et al_. Comparison of clinical outcomes of patients with relapsed acute promyelocytic leukemia induced

with arsenic trioxide and consolidated with either an autologous stem cell transplant or an arsenic trioxide-based regimen. _Biol Blood Marrow Transplant_ 2009; 15: 1479–1484. Article  CAS 

PubMed  Google Scholar  * Yanada M, Tsuzuki M, Fujita H, Fujimaki K, Fujisawa S, Sunami K _et al_. Phase 2 study of arsenic trioxide followed by autologous hematopoietic cell transplantation

for relapsed acute promyelocytic leukemia. _Blood_ 2013; 121: 3095–3102. Article  CAS  PubMed  Google Scholar  * Pemmaraju N, Tanaka MF, Ravandi F, Lin H, Baladandayuthapani V, Rondon G _et

al_. Outcomes in patients with relapsed or refractory acute promyelocytic leukemia treated with or without autologous or allogeneic hematopoietic stem cell transplantation. _Clin Lymphoma

Myeloma Leuk_ 2013; 13: 485–492. Article  PubMed  PubMed Central  Google Scholar  * Fujita H, Asou N, Iwanaga M, Hyo R, Nomura S, Kiyoi H _et al_. Role of hematopoietic stem cell

transplantation for relapsed acute promyelocytic leukemia: a retrospective analysis of JALSG-APL97. _Cancer Sci_ 2013; 104: 1339–1345. Article  CAS  PubMed  PubMed Central  Google Scholar  *

Holter Chakrabarty JL, Rubinger M, Le-Rademacher J, Wang HL, Grigg A, Selby GB _et al_. Autologous is superior to allogeneic hematopoietic cell transplantation for acute promyelocytic

leukemia in second complete remission. _Biol Blood Marrow Transplant_ 2014; 20: 1021–1025. Article  PubMed  Google Scholar  * Kohno A, Morishita Y, Iida H, Yanada M, Uchida T, Hamaguchi M

_et al_. Hematopoietic stem cell transplantation for acute promyelocytic leukemia in second or third complete remission: a retrospective analysis in the Nagoya Blood and Marrow

Transplantation Group. _Int J Hematol_ 2008; 87: 210–216. Article  PubMed  Google Scholar  * Lo-Coco F, Avvisati G, Vignetti M, Thiede C, Orlando SM, Iacobelli S _et al_. Retinoic acid and

arsenic trioxide for acute promyelocytic leukemia. _N Engl J Med_ 2013; 369: 111–121. Article  CAS  PubMed  Google Scholar  * Fenaux P, Chevret S, Guerci A, Fegueux N, Dombret H, Thomas X

_et al_. Long-term follow-up confirms the benefit of all-trans retinoic acid in acute promyelocytic leukemia. European APL group. _Leukemia_ 2000; 14: 1371–1377. Article  CAS  PubMed  Google

Scholar  Download references ACKNOWLEDGEMENTS The online registry for data collection was supported by the companies CEPHALON and TEVA. AUTHOR INFORMATION AUTHORS AND AFFILIATIONS *

Department of Hematology and Oncology, University Hospital Mannheim, University of Heidelberg, Mannheim, Germany E Lengfelder, A Schmidt & W-K Hofmann * Department of Biomedicine and

Prevention, University Tor Vergata, Rome, Italy F Lo-Coco & S M Ramadan * Hopital St Louis, Paris, France L Ades, A M Nloga, B Cassinat & P Fenaux * Department of Hematology,

University Hospital La Fe and Department of Medicine, University of Valencia, Valencia, Spain P Montesinos & M Sanz * Department of Medical and Molecular Genetics, King’s College London,

London, UK D Grimwade * Heartofengland NHS Foundation Trust, Birmingham, UK B Kishore * Evangelismos Hospital, Athens, Greece M Pagoni * Department of Cellular Biotechnology and Hematology,

Sapienza University, Rome, Italy M Breccia * Hospital General de Alicante, Alicante, Spain A J G Huerta * Hospital Insular de Las Palmas, Las Palmas, Spain J D González-Sanmiguel * Service

d’Hématologie du CHUV, Lausanne, Switzerland J-F Lambert * Department of Hematology, Karolinska University Hospital, Stockholm, Sweden S Lehmann * San Bortolo Hospital, Vicenza, Italy E Di

Bona * Institute of Biostatistics and Clinical Research, University of Muenster, Muenster, Germany D Görlich & M-C Sauerland Authors * E Lengfelder View author publications You can also

search for this author inPubMed Google Scholar * F Lo-Coco View author publications You can also search for this author inPubMed Google Scholar * L Ades View author publications You can also

search for this author inPubMed Google Scholar * P Montesinos View author publications You can also search for this author inPubMed Google Scholar * D Grimwade View author publications You

can also search for this author inPubMed Google Scholar * B Kishore View author publications You can also search for this author inPubMed Google Scholar * S M Ramadan View author

publications You can also search for this author inPubMed Google Scholar * M Pagoni View author publications You can also search for this author inPubMed Google Scholar * M Breccia View

author publications You can also search for this author inPubMed Google Scholar * A J G Huerta View author publications You can also search for this author inPubMed Google Scholar * A M

Nloga View author publications You can also search for this author inPubMed Google Scholar * J D González-Sanmiguel View author publications You can also search for this author inPubMed 

Google Scholar * A Schmidt View author publications You can also search for this author inPubMed Google Scholar * J-F Lambert View author publications You can also search for this author

inPubMed Google Scholar * S Lehmann View author publications You can also search for this author inPubMed Google Scholar * E Di Bona View author publications You can also search for this

author inPubMed Google Scholar * B Cassinat View author publications You can also search for this author inPubMed Google Scholar * W-K Hofmann View author publications You can also search

for this author inPubMed Google Scholar * D Görlich View author publications You can also search for this author inPubMed Google Scholar * M-C Sauerland View author publications You can also

search for this author inPubMed Google Scholar * P Fenaux View author publications You can also search for this author inPubMed Google Scholar * M Sanz View author publications You can also

search for this author inPubMed Google Scholar CONSORTIA FOR THE EUROPEAN LEUKEMIANET CORRESPONDING AUTHOR Correspondence to E Lengfelder. ETHICS DECLARATIONS COMPETING INTERESTS Eva

Lengfelder and David Grimwade received research support from CEPHALON and TEVA. Francesco Lo-Coco and Maria Pagoni participated in speaker’s bureau of TEVA. The other authors declare no

conflict of interest. RIGHTS AND PERMISSIONS Reprints and permissions ABOUT THIS ARTICLE CITE THIS ARTICLE Lengfelder, E., Lo-Coco, F., Ades, L. _et al._ Arsenic trioxide-based therapy of

relapsed acute promyelocytic leukemia: registry results from the European LeukemiaNet. _Leukemia_ 29, 1084–1091 (2015). https://doi.org/10.1038/leu.2015.12 Download citation * Received: 14

December 2014 * Revised: 19 January 2015 * Accepted: 21 January 2015 * Published: 28 January 2015 * Issue Date: May 2015 * DOI: https://doi.org/10.1038/leu.2015.12 SHARE THIS ARTICLE Anyone

you share the following link with will be able to read this content: Get shareable link Sorry, a shareable link is not currently available for this article. Copy to clipboard Provided by the

Springer Nature SharedIt content-sharing initiative